Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Good news out of Fortress
January 2018
SHARING OPTIONS:

NEW YORK—Fortress Biotech Inc. recently shared clinical data on therapies being developed at its subsidiaries Caelum Biosciences Inc. and Mustang Bio Inc. The data were presented at the 59th American Society of Hematology Annual Meeting.
 
Dr. Lindsay A. Rosenwald, Fortress Biotech’s chairman, president and CEO, said, “Trial investigators at Columbia concluded that Caelum’s CAEL-101 dosed once weekly demonstrated early and clinically efficacious organ responses throughout a Phase 1a/1b trial, underscoring its potential to be a best-in-class treatment in AL amyloidosis and providing signals to support advancement into a Phase 2b/3 trial in the second half of 2018. In addition, trial investigators at City of Hope found that Mustang Bio’s MB-102 CAR T therapy was safe, well tolerated and achieved a complete response in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm in an ongoing Phase 1 trial. According to City of Hope, this is the first BPDCN patient to achieve a complete response to a CAR T cell therapy.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.